Dapagliflozin, an investigational compound, is a first-in-class sodium-glucose cotransporter-2 (SGLT2) inhibitor and is currently in Phase 3 trials under joint development by Bristol-Myers Squibb and AstraZeneca as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes. SGLT2 inhibitors, which act independently of insulin mechanisms, facilitate the excretion of glucose and associated calories in the urine, thereby lowering blood glucose levels.

"With type 2 diabetes, we often see a progressive deterioration of glycemic control in patients, which may require treatment intensification with additional drug therapy," said Krzysztof Strojek, Professor, Department of Internal Diseases Diabetology & Nephrology Silesian Medical University, Zabrze (Poland), principal investigator of the study. "This study, which adds to the Phase 3 data available for this investigational compound, demonstrated that dapagliflozin improved glycemic control, as measured by HbA1c, FPG and PPG, in adult patients with type 2 diabetes when added to the commonly used oral diabetic agent - glimepiride."

SOURCE Bristol-Myers Squibb Company and AstraZeneca